Cargando…
Anti-TNF-α Therapy for Ankylosing Spondylitis
BACKGROUND: This review evaluated the safety and efficacy of etanercept in patients with ankylosing spondylitis (AS). METHODS: Of 59 patients with AS, this study reviewed 11 patients who were refractory to conventional therapy and treated with etanercept from September 2005 to January 2008. The mean...
Autores principales: | Son, Jung-Hwan, Cha, Sang-Won |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Orthopaedic Association
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2824092/ https://www.ncbi.nlm.nih.gov/pubmed/20190998 http://dx.doi.org/10.4055/cios.2010.2.1.28 |
Ejemplares similares
-
Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice
por: Liu, Bin, et al.
Publicado: (2019) -
Association of anti-TNF-α treatment with gut microbiota of patients with ankylosing spondylitis
por: Dai, Qinghong, et al.
Publicado: (2022) -
Associations of Platelet Count with Inflammation and Response to Anti-TNF-α Therapy in Patients with Ankylosing Spondylitis
por: Qian, Hongyan, et al.
Publicado: (2020) -
Age determines response to anti-TNFα treatment in patients with ankylosing spondylitis and is related to TNFα-producing CD8 cells
por: Schramm-Luc, Agata, et al.
Publicado: (2018) -
Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFα Therapy
por: Suh, Young Sun, et al.
Publicado: (2014)